MHRA GDP/GMP Symposium Overview
The recent GDP/GMP symposiums both concentrated on quality risk management, as compared to a previous emphasis on risk assessment. MHRA inspectors appear increasingly unhappy that pharmaceutical companies appear to be throwing together risk assessments, without...Pharma companies and post-Brexit
MPs were told in December that UK patient involvement in clinical trials will diminish post-Brexit making manufactures less likely to invest here. They were also told that unlocking the potential of patient data held by the NHS may be enough to persuade the...Is your RP always in the loop?
Do you keep your RP informed? Is your RP aware of the little problems you’ve encountered along the way? And the seemingly harmless solutions you’ve applied…